Lung cancer screening with chest computed tomography in people living with HIV: A review by the multidisciplinary CANCERVIH working group

Journal of Thoracic Oncology

Volumn 11, Issue 10, 2016, Pages 1644-1652

  Makinson, Alain ^a   Moing, Vincent Le ^a   Reynes, Jacques ^a   Ferry, Tristan ^b   Lavole, Armelle ^c   Poizot Martin, Isabelle ^d   Pujol, Jean Louis ^e   Spano, Jean Philippe ^f   Milleron, Bernard ^c  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c HÔPITAL TENON   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

Computed tomography; HIV; Lung cancer; Screening; Smoking

Indexed keywords

AGE; AIDS PATIENT; CANCER INCIDENCE; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; FEASIBILITY STUDY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LUNG CANCER; MORBIDITY; MORTALITY RATE; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; AGED; DIAGNOSTIC IMAGING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUMOR; MASS SCREENING; MIDDLE AGED; PATHOLOGY; PROCEDURES; THORAX; X-RAY COMPUTED TOMOGRAPHY;

AGED; HIV INFECTIONS; HUMANS; LUNG NEOPLASMS; MASS SCREENING; MIDDLE AGED; THORAX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84991096970     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.06.026     Document Type: Review

References (86)

1. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A:D): a multicohort collaboration. Lancet. 2014;384: 241-248.
2. Kowalska JD, Reekie J, Mocroft A, et al. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS. 2012;26:315-323.
3. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28:1181-1191.
4. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009;52:203-208.
5. Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS. 2014;28: 881-890.
6. Lanoy E, Spano JP, Bonnet F, et al. The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer. 2011;129:467-475.
7. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753-762.
8. Hleyhel M, Cancer risk group of the French hospital database on HIV. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS. 2014;28:2109-2118.
9. Shiels MS, Cole SR, Mehta SH, Kirk GD. Lung cancer incidence and mortality among HIV-infected and HIVuninfected injection drug users. J Acquir Immune Defic Syndr. 2010;55:510-515.
10. Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS. 2007;21:207-213.
11. Hleyhel M, Belot A, Bouvier AM, et al. Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. Int J Cancer. 2015;137:2443-2453.
12. Gotti D, Raffetti E, Albini L, et al. Survival in HIVinfected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study. PLoS One. 2014;9:e94768.
13. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645-1654.
14. Dal Maso L, Polesel J, Serraino D, et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer. 2009;100:840-847.
15. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a metaanalysis. Lancet. 2007;370:59-67.
16. van Leeuwen MT, Vajdic CM, Middleton MG, et al. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS. 2009;23:2183-2190.
17. Tron L, Lert F, Spire B, Dray-Spira R, ANRS-Vespa2 Study Group. Tobacco smoking in HIV-infected versus general population in france: heterogeneity across the various groups of people living with HIV. PLoS One. 2014;9: e107451.
18. Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: crosssectional surveys. Ann Intern Med. 2015;162:335-344.
19. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10:1152-1159.
20. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
21. Sigel K, Crothers K, Dubrow R, et al. Prognosis in HIVinfected patients with non-small cell lung cancer. Br J Cancer. 2013;109:1974-1980.
22. Marcus JL, Chao C, Leyden WA, et al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015;24:1167-1173.
23. Aberle DR, Adams AM, Berg CD, et al. Reduced lungcancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
24. Aberle DR, DeMello S, Berg CD, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013;369:920-931.
25. National Lung Screening Trial Research Trial Team, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980-1991.
26. Gould MK. Clinical practice. Lung-cancer screening with low-dose computed tomography. N Engl J Med. 2014;371:1813-1820.
27. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009;361:2221-2229.
28. Pedersen JH, Ashraf H, Dirksen A, et al. The Danish randomized lung cancer CT screening trial-overall design and results of the prevalence round. J Thorac Oncol. 2009;4:608-614.
29. Baldwin DR, Duffy SW, Wald NJ, Page R, Hansell DM, Field JK. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax. 2011;66:308-313.
30. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120: 868-874.
31. Infante M, Cavuto S, Lutman FR, et al. Long-term followup results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med. 2015;191:1166-1175.
32. Lopes Pegna A, Picozzi G, Falaschi F, et al. Four-year results of low-dose CT screening and nodule management in the ITALUNG trial. J Thorac Oncol. 2013;8: 866-875.
33. Blanchon T, Brechot JM, Grenier PA, et al. Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer. 2007;58:50-58.
34. Hulbert A, Hooker CM, Keruly JC, et al. Prospective CT screening for lung cancer in a high-risk population: HIVpositive smokers. J Thorac Oncol. 2014;9:752-759.
35. Makinson A, Eymard-Duvernay S, Raffi F, et al. Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers. AIDS. 2016;30:573-582.
36. Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J. 2013;42:1659-1667.
37. Sigel K, Wisnivesky J, Shahrir S, et al. Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening. AIDS. 2014;28:1007-1014.
38. International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1763-1771.
39. Pinsky PF, Berg CD. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? J Med Screen. 2012;19:154-156.
40. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160:311-320.
41. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med. 2010;153:452-460.
42. Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst. 2015;107:dju503.
43. Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368:728-736.
44. Pinsky PF, Zhu CS, Kramer BS. Lung cancer risk by years since quitting in 30+ pack year smokers. J Med Screen. 2015;22:151-157.
45. Henschke CI, Yip R, Yankelevitz DF, Smith JP, International Early Lung Cancer Action Program I. Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. Ann Intern Med. 2013;158:246-252.
46. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013;369:910-919.
47. Ilie M, Hofman V, Long-Mira E, et al. "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One. 2014;9:e111597.
48. van den Bergh KA, Essink-Bot ML, Borsboom GJ, Scholten ET, van Klaveren RJ, de Koning HJ. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. Eur Respir J. 2011;38:154-161.
49. Byrne MM, Weissfeld J, Roberts MS. Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening. Med Decis Making. 2008;28:917-925.
50. Gareen IF, Duan F, Greco EM, et al. Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial. Cancer. 2014;120:3401-3409.
51. Brenner DJ. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology. 2004;231:440-445.
52. Mascalchi M, Mazzoni LN, Falchini M, et al. Dose exposure in the ITALUNG trial of lung cancer screening with low-dose CT. Br J Radiol. 2012;85:1134-1139.
53. Kong CY, Lee JM, McMahon PM, et al. Using radiation risk models in cancer screening simulations: important assumptions and effects on outcome projections. Radiology. 2012;262:977-984.
54. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CTscreening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21: 308-315.
55. Patz EF Jr, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174:269-274.
56. Couraud S, Greillier L, Milleron B, Group ILCS. Estimating overdiagnosis in lung cancer screening. JAMA Intern Med. 2014;174:1197.
57. Sigel KM. The cost-effectiveness of lung cancer screening in HIV infection. http://grantome.com/grant/ NIH/K07-CA180782-02. Accessed August 9, 2016.
58. Mets OM, de Jong PA, Prokop M. Computed tomographic screening for lung cancer: an opportunity to evaluate other diseases. JAMA. 2012;308:1433-1434.
59. Jacobs PC, Isgum I, Gondrie MJ, et al. Coronary artery calcification scoring in low-dose ungated CT screening for lung cancer: interscan agreement. AJR Am J Roentgenol. 2010;194:1244-1249.
60. Mets OM, Vliegenthart R, Gondrie MJ, et al. Lung cancer screening CT-based prediction of cardiovascular events. JACC Cardiovasc Imaging. 2013;6:899-907.
61. Sverzellati N, Cademartiri F, Bravi F, et al. Relationship and prognostic value of modified coronary artery calcium score, FEV1, and emphysema in lung cancer screening population: the MILD trial. Radiology. 2012;262:460-467.
62. Jacobs PC, Gondrie MJ, van der Graaf Y, et al. Coronary artery calcium can predict all-cause mortality and cardiovascular events on low-dose CT screening for lung cancer. AJR Am J Roentgenol. 2012;198:505-511.
63. Takx RA, Isgum I, Willemink MJ, et al. Quantification of coronary artery calcium in nongated CT to predict cardiovascular events in male lung cancer screening participants: results of the NELSON study. J Cardiovasc Comput Tomogr. 2015;9:50-57.
64. Henschke CI, Yip R, Boffetta P, et al. CT screening for lung cancer: importance of emphysema for never smokers and smokers. Lung Cancer. 2015;88:42-47.
65. Camiciottoli G, Cavigli E, Grassi L, et al. Prevalence and correlates of pulmonary emphysema in smokers and former smokers. A densitometric study of participants in the ITALUNG trial. Eur Radiol. 2009;19:58-66.
66. Mohamed Hoesein FA, de Hoop B, Zanen P, et al. CTquantified emphysema in male heavy smokers: association with lung function decline. Thorax. 2011;66:782-787.
67. Sverzellati N, Guerci L, Randi G, et al. Interstitial lung diseases in a lung cancer screening trial. Eur Respir J. 2011;38:392-400.
68. de Jong WU, de Jong PA, Vliegenthart R, et al. Association of COPD and smoking status with bone density and vertebral fractures in male lung cancer screening participants. J Bone Miner Res. 2014;29:2224-2229.
69. Makinson A, Eymard-Duvernay S,Bouassida I, et al.Coronary artery calcification on chest computed tomography in HIVinfected smokers [abstract]. http://www.croiconference. org/sessions/coronary-artery-calcification-chest-computedtomography-hiv-infected-smokers. Accessed August 9, 2016.
70. Thouvenin Y, Makinson A, Cournil A, et al. Chest lowdose computed tomography for early lung cancer diagnosis as an opportunity to diagnose vertebral fractures in HIV-infected smokers, an ANRS EP48 HIV CHESTsubstudy. J Acquir Immune Defic Syndr. 2015;69:299-305.
71. Makinson A, Hayot M, Eymard-Duvernay S, et al. High prevalence of undiagnosed COPD in a cohort of HIV-infected smokers. Eur Respir J. 2015;45:828-831.
72. Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer. 1996;15:325-339.
73. Tanner NT, Kanodra NM, Gebregziabher M, et al. The Association Between Smoking Abstinence and Mortality in the National Lung Screening Trial. Am J Respir Crit Care Med. 2016;193:533-541.
74. Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727-734.
75. Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health. 2010;100:1896-1903.
76. van der Aalst CM, van den Bergh KA, Willemsen MC, de Koning HJ, van Klaveren RJ. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax. 2010;65:600-605.
77. Ashraf H, Saghir Z, Dirksen A, et al. Smoking habits in the randomised Danish Lung Cancer Screening Trial with low-dose CT: final results after a 5-year screening programme. Thorax. 2014;69:574-579.
78. van der Aalst CM, van Klaveren RJ, van den Bergh KA, Willemsen MC, de Koning HJ. The impact of a lung cancer computed tomography screening result on smoking abstinence. Eur Respir J. 2011;37:1466-1473.
79. Anderson CM, Yip R, Henschke CI, Yankelevitz DF, Ostroff JS, Burns DM. Smoking cessation and relapse during a lung cancer screening program. Cancer Epidemiol Biomarkers Prev. 2009;18:3476-3483.
80. Styn MA, Land SR, Perkins KA, Wilson DO, Romkes M, Weissfeld JL. Smoking behavior 1 year after computed tomography screening for lung cancer: Effect of physician referral for abnormal CT findings. Cancer Epidemiol Biomarkers Prev. 2009;18:3484-3489.
81. Tammemagi MC, Berg CD, Riley TL, Cunningham CR, Taylor KL. Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst. 2014;106: dju084.
82. Townsend CO, Clark MM, Jett JR, et al. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer. 2005;103: 2154-2162.
83. Mimiaga MJ, Reisner SL, Grasso C, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health. 2013;103: 1457-1467.
84. Daskalopoulou M, Rodger A, Phillips AN, et al. Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Lancet HIV. 2014;1:e22-e31.
85. Keith A, Dong Y, Shuter J, Himelhoch S. Behavioral interventions for tobacco use in HIV-infected smokers: a meta-analysis. J Acquir Immune Defic Syndr. 2016;72: 527-533.
86. Marcie P, Roussillon C, Katlama C, et al. Varenicline vs placebo for smoking cessation: ANRS 144 inter-ACTIV randomized trial [abstract]. http://www.croiconference. org/sessions/varenicline-vs-placebo-smoking-cessationanrs-144-inter-activ-randomized-trial. Accessed August 9, 2016.